Filing Flows › Teladoc Health (TDOC) › Q2 2026 › vs Q1 2026
Teladoc Health (TDOC) Q2 2026 vs Q1 2026 (quarter over quarter)
Teladoc Health's revenue fell $6.9M (-1%) from $614M in Q1 2026 to $607M in Q2 2026. The biggest changes: Access Fees −$10.4M (-2%); Other +$3.5M (+3%).
Teladoc Health, Q2 2026: revenue $607M (-4% year over year), operating margin -6.1%, net loss $38.9M, operating cash flow $64.7M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 10.5% | 1.3% | +9.2 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Access Fees | $474M | $485M | −$10.4M | -2% |
| Other | $133M | $129M | $3.5M | +3% |
| Revenue | $607M | $614M | −$6.9M | -1% |
| Net loss | $38.9M | $63.8M | −$24.9M | -39% |
| Costs & expenses | $646M | $679M | −$32.8M | -5% |
| Operating costs | $644M | $676M | −$31.6M | -5% |
| Income tax | $997K | $3.0M | −$2.0M | -67% |
| Cost of revenue | $191M | $198M | −$6.7M | -3% |
| Research & development | $62.9M | $67.9M | −$5.0M | -7% |
| Sales & marketing | $143M | $152M | −$8.1M | -5% |
| General & admin | $104M | $102M | $1.9M | +2% |
| Other operating costs | $143M | $157M | −$13.7M | -9% |
| Operating cash sources | $104M | $73.4M | $30.2M | +41% |
| Share-based compensation | $9.3M | $14.6M | −$5.3M | -36% |
| Working capital & other | $94.3M | $58.7M | $35.5M | +60% |
| Net loss absorbed | $38.9M | $63.8M | −$24.9M | -39% |
| Operating cash flow | $64.7M | $9.5M | $55.1M | +580% |
| Free cash flow (OCF − capex) | $63.7M | $7.9M | $55.9M | +711% |
| Capital expenditures | $928K | $1.7M | −$732K | -44% |
Questions
How much did Teladoc Health's revenue grow quarter over quarter in Q2 2026?
Teladoc Health's revenue fell $6.9M (-1%) from $614M in Q1 2026 to $607M in Q2 2026.
What drove Teladoc Health's revenue change in Q2 2026?
Access Fees −$10.4M (-2%); Other +$3.5M (+3%).